Abatacept in biologic-refractory juvenile idiopathic arthritis-associated uveitis: a case-based review. (PubMed, Clin Rheumatol) - Oct 7, 2026 - "Abatacept may be a useful therapeutic option for JIA-associated uveitis refractory to anti-TNF agents and tocilizumab. Ocular response may occur despite persistent or recurrent articular activity, suggesting that ocular and articular outcomes should be assessed separately. Larger prospective studies are needed to better define the role of abatacept in refractory JIA-associated uveitis."
Journal • Review • Dermatology • Idiopathic Arthritis • Immunology • Infectious Disease • Ocular Inflammation • Oncology • Ophthalmology • Pediatrics • Rheumatology • Uveitis
|
|
Emil Aliyev; Erdal Sag; Figen Bezci Aygun; Seza Ozen; Sibel Kadayifcilar; Veysel Cam; Yelda Bilginer
|